NRG Oncology's Phase 2 Trial of SBRT for Oligometastatic Breast Cancer Fails to Improve PFS
Validating the Local Control Paradigm for Oligometastatic Breast Cancer
This Phase II NRG-BR002 trial investigated patients with oligometastatic breast cancer (OMBC), defined as having four or fewer metastatic lesions. The study aimed to determine whether adding local consolidation therapy (LCT), such as stereotactic body radiotherapy (SBRT) or surgical resection, to standard-of-care systemic therapy could improve survival. This represented an innovative approach to disrupt the disease's progression through physical removal. However, the clinical trial failed to demonstrate any additional benefit of local therapy, causing significant disappointment in the academic community.
Failure to Improve Primary Endpoint: Progression-Free Survival
The study results showed that the group of patients who received local therapy did not demonstrate a statistically significant improvement in progression-free survival (PFS), the primary endpoint. The hazard ratio (HR) was 0.92 (95% confidence interval, 0.71 to 1.17), and the one-sided log-rank p-value was 0.36, failing to meet the pre-defined efficacy criterion of a hazard ratio of 0.55. Furthermore, the secondary endpoint of overall survival (OS) also did not show statistical significance, with a p-value of 0.54, leading to the termination of the Phase 3 trial.
Impact on the Global Radiation Equipment Market and the Pharmaceutical Industry
These results have hindered the expansion of indications for SBRT technology, such as Varian Medical Systems' TrueBeam and Elekta's Versa HD, which are leading products in the global radiation therapy equipment market. The potential for creating new demand in the breast cancer segment of the precision radiation therapy market, which was projected to grow to billions of dollars, has been significantly reduced. From the perspective of the pharmaceutical industry, the study provides clinical justification for focusing on optimizing standard systemic therapies, such as chemotherapy or hormone therapy, rather than combining them with aggressive local therapies in patients with oligometastatic disease.
Maintaining Standard Treatment Guidelines and Future Research Directions
The American Society of Clinical Oncology (ASCO) and major cancer centers have reaffirmed their guidelines, stating that SBRT and other local therapies should not be recommended as standard treatment for patients with oligometastatic breast cancer, based on the results of this trial. However, the researchers believe that the trial, despite its negative results, demonstrated that a prospective, randomized controlled trial in metastatic patients is feasible. Future research is expected to focus on precision medicine approaches, such as tumor genomic profiling or specific biomarker analysis, to identify a small subset of patients who may benefit from local therapy.
The failure of the NRG Oncology-sponsored Phase 2 trial (NRG-BR002) for oligometastatic breast cancer has put a damper on the industry's mid-to-long-term strategy of expanding indications by combining standard systemic therapy with local therapies such as SBRT to achieve a hazard ratio of 0.55. As a result, the short-term momentum for device adoption in the breast cancer segment of the global radiation therapy market, which Varian's TrueBeam and Elekta's Versa HD target, is expected to slow down. Researchers will use the concrete data of hazard ratio (HR) 0.92 (p=0.36) for progression-free survival (PFS) and p-value 0.54 for overall survival (OS) to reconfirm the superiority of standard systemic therapy and explore new biomarkers for patient selection. For clinical professionals, the trial provides a valuable lesson that when designing randomized controlled trials for oligometastatic solid tumors, the control level of the standard systemic therapy group and the timing of local consolidation therapy must be designed more precisely.
Source: ClinicalTrials.gov (api_ct)